Výsledky vyhledávání - "Sidsel Marie Tønder"

Surgeries and Diagnostic Procedures in Heni ophilia Patients on Concizumab Prophylaxis: Results from the Phase 2 Explorer4 and Explorer5 Trials

Autor: Allison P. Wheeler, Gary Benson, Hermann Eichler, Sidsel Marie Tønder, Katarina Cepo, Victor Jimenez Yuste, Kaan Kavakli, Lily LL Wong, Tadashi Matsushita

Introduction: Concizumab is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody in phase 3 clinical development as a once-daily, subcutaneous prophylaxis across all hemophilia subtypes. The phase 2 trials explorer4 (NCT03196284) and ex

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f86f6aa9bb63fcec91139163f94f051a
https://hdl.handle.net/11454/77782

Zobrazit plný text záznamu

Improvement in Health-Related Quality of Life Measures after Long-Term, Daily, Subcutaneous Concizumab Prophylaxis in Patients with Hemophilia A/B with and without Inhibitors: Results from the Main and Extension Parts of Phase 2 Clinical Trials

Autor: Sidsel Marie Tønder, Mathilde Faller, Thomas Porstmann

Publikováno v: Blood. 138:1041-1041

Relative to the general population, health-related quality of life (HRQoL) is impaired in patients with hemophilia, who report increased pain and reduced physical activity. It is therefore of interest to assess the change in HRQoL after long-term pro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::391b63f4c3804f6494a309dce70e0c1a
https://doi.org/10.1182/blood-2021-152257

Zobrazit plný text záznamu

Safety and Longer-Term Efficacy of Concizumab Prophylaxis in Patients with Hemophilia a or b with Inhibitors: Results from the Extension Part of the Phase 2 explorer4 Trial

Autor: Tadashi Matsushita, Silva Zupančić-Šalek, Katarina Cepo, Victor Jiménez Yuste, Lone Hvitfeldt Poulsen, Giancarlo Castaman, Amy D. Shapiro, Guy Young, Sidsel Marie Tønder

Publikováno v: Blood. 136:40-41

Introduction Concizumab is a high-affinity, anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody currently in clinical investigation for the once-daily subcutaneous prophylactic treatment of patients with hemophilia. We present results fro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::466cc7a84755911e653e3289645642c6
https://doi.org/10.1182/blood-2020-139910

Zobrazit plný text záznamu

Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial)

Autor: Pål Andre Holme, Elena Santagostino, Steven R. Lentz, Claude Negrier, Andrea Landorph, Mudi Misgav, Canan Albayrak, Allison P. Wheeler, Miguel A. Escobar, Robert Klamroth, Nicola Curry, Susan Kearney, Sidsel Marie Tønder, Midori Shima

Publikováno v: Haemophilia

Curry, Nicola/0000-0002-3849-0688; Escobar, Miguel/0000-0002-2944-0240 WOS: 000470929100022 PubMed: 30817066 Introduction Turoctocog alfa pegol (N8-GP) is a site-specific, 40 kDa glycoPEGylated recombinant factor VIII (FVIII) product with an extended

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5662f7793ce8038f413ccd71e57da22a
https://hdl.handle.net/20.500.12712/10847

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání